The Benefits of Real-Time Nonclinical Safety Data Analysis Blog Post
Learn how SEND Explorer software helps nonclinical drug developers streamline performing real-time toxicology assessments of investigational drugs.
Simcyp Specialized Modules Page
Simcyp™ specialized modules Simcyp expansions Further to the work with the Simcyp Consortium, the Certara Simcyp team collaborates with other organizations and funds research to develop unique modules. While connected...
Understanding Variability in CAR-T Cell Therapy Kinetics Blog Post
Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates substantial inter-individual variability in cellular kinetics. This variability complicates predicting therapeutic outcomes and managing associated...
Market access and commercial Page
Maximize your drug’s valueMarket access and commercial Craft persuasive value stories with integrated, evidence-based solutions Certara Market Access and Commercial solutions empower you to craft compelling value propositions with integrated...
Preclinical Page
Accelerate your drug development with Certara’s preclinical and early clinical solutions, tailored to your unique needs.
Discovery Page
Better discovery is insightDiscovery Transform discovery into a strategic asset Innovate with confidence by turning your discovery process into a competitive advantage. With Certara’s tools for data-driven design, analysis, synthesis tracking,...
Certara Awarded European Medicines Agency Project to Assess Real-World Data Landscape for CAR-T Cell Therapies Blog Post
January 22, 2025 Project will evaluate content, quality, and accessibility of available real-world data sources for six CAR-T cell therapies currently approved for use in the European Union (EU) Radnor,...Regulatory Page
Navigate complex regulatory landscapes seamlessly.
